Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLIN.L Share News (CLIN)

  • There is currently no data for CLIN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Clinigen FY revenues continue to rise, profit growth slowed by Covid-19

Tue, 14th Jul 2020 09:07

(Sharecast News) - Pharmaceutical group Clinigen warned full-year profit growth would be at the lower end of guidance as a result of the Covid-19 pandemic and the launch of a low-cost competitor to its Foscavir drug.
Although 2021 was said to be the lower end of guidance, Clinigen still anticipates medium-term organic profit growth will be 5-10%, the company said on Tuesday

Clinigen highlighted that the effect of Covid-19, expected to be felt in the first quarter of the current year, would result in underlying earnings taking a hit of roughly £8m - primarily related to the disrupted launch of its cancer treatment, Proleukin.

Revenues for fiscal 2020 were estimated to have grown roughly 17% at constant currencies - or 13% on a gross reported basis.

The AIM-listed group added that underlying earnings were predicted to have grown at least 29% year-on-year, while cash conversion was said to have returned to "normal levels" in the second half - with net debt of £312m.

Chief executive Shaun Chilton said: "We continue to see organic growth in line with our medium-term guidance at this early stage of the new financial year, despite Covid-19 and expected competitive pressure to Foscavir.

"As we look beyond FY21, we see growth significantly accelerating as we onboard new asset Erwinase and we continue to gain share in the end-markets we serve."

As of 0905 BST, Clinigen shares had sunk 10.82% to 709p.
More News
1 Apr 2022 20:22

IN BRIEF: UK court sanctions Titon takeover of Clinigen

Clinigen Group PLC - Burton On Trent, Staffordshire-based pharmaceutical services - Says Thursday that its takeover by Triton Investment Management Ltd has been sanctioned by the High Court of Justice in England and Wales. Shares will be cancelled from trading on AIM on Tuesday.

Read more
23 Feb 2022 19:06

TRADING UPDATES: IPF swings to profit; Seraphine lowers outlook

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
23 Feb 2022 13:28

Clinigen revenue rises as shareholders approve its acquisition

(Sharecast News) - Pharmaceuticals and service company Clinigen Group reported a 10% improvement in net revenue from continuing operations in its half-year results on Wednesday, or 14% on an organic basis, to £238.1m.

Read more
16 Feb 2022 10:09

IN BRIEF: Clinigen expects acquisition by Triton to complete in April

Clinigen Group PLC - Burton On Trent, Staffordshire-based pharmaceutical services - Says its acquisition by funds managed by Triton Investment Management Ltd is likely to complete in early April, with its shares due to be cancelled on AIM on April 5. The deal and timeline are subject to antitrust and foreign investment approvals. Triton, a private equity firm submitted a cash offer of 925 pence per share, valuing Clinigen at GBP1.3 billion, which was approved by shareholders last Tuesday. The latest date for completion is September 8.

Read more
9 Feb 2022 10:38

IN BRIEF: Clinigen signs global distribution deal for Qinlock

IN BRIEF: Clinigen signs global distribution deal for Qinlock

Read more
8 Feb 2022 14:41

IN BRIEF: Clinigen shareholders approve takeover by Triton funds

IN BRIEF: Clinigen shareholders approve takeover by Triton funds

Read more
17 Jan 2022 10:05

Triton increases takeover bid for Clinigen to GBP1.3 billion

Triton increases takeover bid for Clinigen to GBP1.3 billion

Read more
17 Jan 2022 07:29

Triton makes 'increased and final' 925p bid for Clinigen

(Sharecast News) - Clinigen announced an increased and final all-cash offer from Triton of 925p per share on Monday.

Read more
12 Jan 2022 11:49

Clinigen reiterates guidance after 'solid' first half

(Sharecast News) - Pharmaceutical products and services company Clinigen reiterated its guidance for EBITDA growth in the 2022 financial year of between 5% and 10% in a trading update on Wednesday.

Read more
12 Jan 2022 11:13

Clinigen holds earnings growth guidance after solid first half

Clinigen holds earnings growth guidance after solid first half

Read more
11 Jan 2022 14:59

CORRECT: UK shareholder meetings calendar - next 7 days

CORRECT: UK shareholder meetings calendar - next 7 days

Read more
11 Jan 2022 14:46

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
29 Dec 2021 15:55

UK dividends calendar - next 7 days

UK dividends calendar - next 7 days

Read more
8 Dec 2021 11:56

Drugmaker Clinigen agrees to Triton's GBP1.2 billion takeover bid

Drugmaker Clinigen agrees to Triton's GBP1.2 billion takeover bid

Read more
8 Dec 2021 11:45

AIM WINNERS & LOSERS: Rockhopper rises as Navitas enters project

AIM WINNERS & LOSERS: Rockhopper rises as Navitas enters project

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.